Literature DB >> 17991354

Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer.

Robert L Coleman.   

Abstract

Entities:  

Year:  2007        PMID： 17991354     DOI： 10.1007/s11912-007-0065-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  8 in total

1.  Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.

Authors:  G Bolis; G Scarfone; G Giardina; A Villa; G Mangili; M Melpignano; M Presti; S Tateo; M Franchi; F Parazzini
Journal:  Gynecol Oncol       Date:  2001-04       Impact factor: 5.482

Review 2.  Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

Authors:  K Jaaback; N Johnson
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

3.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

Authors:  Jacobus Pfisterer; Marie Plante; Ignace Vergote; Andreas du Bois; Hal Hirte; Angel J Lacave; Uwe Wagner; Anne Stähle; Gavin Stuart; Rainer Kimmig; Sigrid Olbricht; Tien Le; Janusz Emerich; Walther Kuhn; James Bentley; Christian Jackisch; Hans-Joachim Lück; Justine Rochon; Annamaria Hayden Zimmermann; Elizabeth Eisenhauer
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

4.  Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.

Authors:  A du Bois; H J Lück; J Pfisterer; W Schroeder; J U Blohmer; R Kimmig; V Moebus; J Quaas
Journal:  Ann Oncol       Date:  2001-08       Impact factor: 32.976

5.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

Authors:  M K B Parmar; J A Ledermann; N Colombo; A du Bois; J-F Delaloye; G B Kristensen; S Wheeler; A M Swart; W Qian; V Torri; I Floriani; G Jayson; A Lamont; C Tropé
Journal:  Lancet       Date:  2003-06-21       Impact factor: 79.321

6.  Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.

Authors:  Peter G Rose; Kim Mossbruger; Nancy Fusco; Mary Smrekar; Sue Eaton; Michael Rodriguez
Journal:  Gynecol Oncol       Date:  2003-01       Impact factor: 5.482

7.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

8.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Authors:  Paul A Vasey; Gordon C Jayson; Alan Gordon; Hani Gabra; Rob Coleman; Ronnie Atkinson; David Parkin; James Paul; Andrea Hay; Stan B Kaye
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.